Virus Or Bacteriophage, Except For Viral Vector Or Bacteriophage Vector; Composition Thereof; Preparation Or Purification Thereof; Production Of Viral Subunits; Media For Propagating Patents (Class 435/235.1)
Inactivation or attenuation; producing viral subunits (Class 435/236)
Recovery or purification (Class 435/239)
  • Alpha-4-beta-7 heterodimer specific antagonist antibody
    Patent number: 8871490
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: October 28, 2014
    Assignee: Amgen Inc.
    Inventors: Hailing Hsu, Ian Foltz, Frederick Jacobsen, Taruna Arora
  • Newcastle disease virus vectored avian vaccines
    Patent number: 8871220
    Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: October 28, 2014
    Assignee: Merial Limited
    Inventors: Michel Bublot, Frederic Reynard, François-Xavier Le Gros
  • Compositions, methods and uses for inducing viral growth
    Patent number: 8871487
    Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: October 28, 2014
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
  • SIMIAN (GORILLA) ADENOVIRUS OR ADENOVIRAL VECTORS AND METHODS OF USE
    Publication number: 20140314717
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
    Type: Application
    Filed: October 5, 2012
    Publication date: October 23, 2014
    Inventors: Douglas E. Brough, Jason G.D. Gall, Duncan McVey
  • HERPES SIMPLEX VIRUS VACCINES
    Publication number: 20140314811
    Abstract: The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.
    Type: Application
    Filed: July 1, 2014
    Publication date: October 23, 2014
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Feng YAO
  • IN-VITRO DIAGNOSTICS FOR CAPRINE ARTHRITIS-ENCEPHALITIS VIRUS ANTISERA AND OTHER VIRAL INTERFERENCE RELATED AGENTS
    Publication number: 20140315186
    Abstract: Various postulates and methodologies in using Caprine Arthritis Encephalitis Virus and other related agents to diagnose and treat HIV/AIDS as well as other related and/or non-related diseases are declared.
    Type: Application
    Filed: April 18, 2013
    Publication date: October 23, 2014
    Inventor: SAM CHACHOUA
  • SYNTHESIS OF LINEAR AND BRANCHED POLYMERS OF POLYPEPTIDES THROUGH DIRECT CONJUGATION
    Publication number: 20140315276
    Abstract: Methods are provided for a one step synthesis of polypeptide polymers or co-polymers. The polymers or co-polymers can be linear or branched. In the methods of the invention, the coding sequence for the polypeptide(s) to be polymerized is altered by introducing one or more codons for an nonnatural amino acid, which coding sequence is then utilized to produce the cognate polypeptide. The nonnatural amino acids are selected to be reactive with each other in a bioorthogonal reaction, and are combined in a conjugation reaction with the desired components of the polymer.
    Type: Application
    Filed: March 4, 2014
    Publication date: October 23, 2014
    Inventors: Cem Albayrak, James R. Swartz, Yuan Lu
  • INFECTIOUS CDNA CLONE OF EUROPEAN PRRS VIRUS AND USES THEREOF
    Publication number: 20140314808
    Abstract: The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the genome of an infectious genotype I (EU) PRRS virus clone useful for studying Porcine Reproductive and Respiratory Syndrome (PRRS), a viral disease affecting swine, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of PRRS.
    Type: Application
    Filed: July 30, 2012
    Publication date: October 23, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GBMH
    Inventors: Christiane Fetzer, Andreas Gallie
  • NOVEL METHOD
    Publication number: 20140315277
    Abstract: The present invention relates to a method for degrading host cell nucleic acids associated with a virus or a viral antigen thereof produced by cell culture, the method comprising at least two steps of nucleic acids degradation with a compound selected from i) an endonuclease and ii) a DNA alkylating agent.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 23, 2014
    Applicant: GlaxoSmithKline Biologicals s. a.
    Inventors: Bruno Rene ANDRE, Benoit Paul Suzanne Champluvier, Benedicte Van Der Hayden
  • RECOMBINASE-BASED LOGIC AND MEMORY SYSTEMS
    Publication number: 20140315310
    Abstract: The invention provides, inter alia, recombinase-based systems that provide for integrated logic and memory in living cells.
    Type: Application
    Filed: December 13, 2013
    Publication date: October 23, 2014
    Applicant: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Piro Siuti
  • Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
    Publication number: 20140314807
    Abstract: The present invention relates to compositions comprising replication defective Schmallenberg virus vaccines, methods of producing the vaccines, and the administration of such vaccines to animals, including ovines and bovines. The invention further relates to methods for providing long-term protective immunity against Schmallenberg in animals, including ovines and bovines.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 23, 2014
    Applicant: MERIAL LIMITED
    Inventor: Jules Maarten Minke
  • Bacteriophages for reducing toxicity of bacteria
    Patent number: 8865158
    Abstract: A genetically modified bacteriophage is disclosed which comprises: (i) an exogenous polynucleotide which encodes an agent which reduces the toxicity of a bacterium; and (ii) an exogenous polynucleotide which encodes a selectable marker. Uses thereof and kits comprising same are also disclosed.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: October 21, 2014
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Ehud Qimron, Rotem Edgar, Nir Friedman
  • Method for producing continuous cell lines
    Patent number: 8865450
    Abstract: The present invention relates to a method for production of continuous cell lines comprising providing living cells of an animal or a human, irradiating said cells with UV light, proliferating said cells and selecting multiplying cells as cells of a continuous cell line.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: October 21, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Manfred Reiter, Wolfgang Mundt, Simone Feigl, Simone Von Fircks
  • PEPTIDE BINDING TO GRAPHITIC MATERIALS AND PHAGE INCLUDING SAME
    Publication number: 20140309126
    Abstract: The present disclosure provides a peptide including one or more amino acid sequence selected from a group consisting of SEQ ID NO 1 and SEQ ID NO 2 and binding specifically to a graphitic material, a phage including same, and a graphitic material including a graphitic surface on which the peptide or the phage is arranged.
    Type: Application
    Filed: February 4, 2014
    Publication date: October 16, 2014
    Applicant: Korea Institute of Science and Technology
    Inventors: Hyunjung YI, Ki Young LEE, Chaun JANG, Joonyeon CHANG
  • ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20140308276
    Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
    Type: Application
    Filed: February 9, 2012
    Publication date: October 16, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
  • USE OF MICRORNAS TO CONTROL VIRUS HELPER NUCLEIC ACIDS
    Publication number: 20140308312
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Application
    Filed: February 5, 2014
    Publication date: October 16, 2014
    Applicant: ALPHAVAX, INC.
    Inventors: Vernon McNeil Coffield, III, Kurt I. Kamrud, Jonathan F. Smith
  • ADENOVIRUS PRODUCING NOVEL CELL LINE AND THE USE THEREOF
    Publication number: 20140308704
    Abstract: The present invention relates to a cell line in which an expression construct is introduced into a genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus E1 coding gene sequence of SEQ ID NO:1 operatively linked to the promoter. According to the present invention, the cell line of the present invention is a novel cell line which is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the present invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus.
    Type: Application
    Filed: November 22, 2012
    Publication date: October 16, 2014
    Inventors: Seung Shin Yu, Chang-Wan Joo, Jin-A Chae, Yeon Suk Cha
  • Dengue and West Nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
    Patent number: 8859240
    Abstract: The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: October 14, 2014
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Frédéric Tangy, Philippe Despres, Chantal Combredet, Marie Pascale Frenkiel
  • Vaccinia virus mutants containing the major genomic deletions of MVA
    Patent number: 8859257
    Abstract: The present invention provides modified vaccinia virus (VACV) genomes as well as vectors, especially viral vectors comprising the same. The present invention further provides modified vaccinia viruses. The present invention further provides methods for determining the effect of mutations in VACV with regard to competence for replication in certain cell types. The present invention further provides methods of preparing modified vaccinia viruses.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: October 14, 2014
    Assignee: Bavarian Nordic A/S
    Inventors: Jürgen Hausmann, Christine Meisinger-Henschel, Mark Suter
  • Recombinant hydrogen-producing cyanobacterium and uses thereof
    Patent number: 8859744
    Abstract: A recombinant cyanobacterium comprising an oxygen-tolerant, hydrogen-evolving hydrogenase, kit, and methods of use.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: October 14, 2014
    Assignee: Synthetic Genomics, Inc.
    Inventors: Qing Xu, Hamilton O. Smith
  • Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
    Patent number: 8859231
    Abstract: Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a different influenza subtype are also described, as are VLPs in which a portion or all of HA or NA is replaced by a heterologous moiety not produced by influenza virus, so as to comprise chimeric VLPs.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: October 14, 2014
    Assignee: Wyeth LLC
    Inventors: Jose M. Galarza, Theresa E. Latham
  • Recombinant Phage and Bacterial Detection Methods
    Publication number: 20140302487
    Abstract: Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of such phage and articles of manufacture comprising such phage, among other things.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 9, 2014
    Inventors: Michael Sandor Koeris, Robert Patrick Shivers, Daniel Robert Brownell, Jason Wyatt Holder, Jayson Linn Bowers
  • NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 1B, HEPATITIS C VIRUS GENOME-REPLICATING CELLS TRANSFECTED WITH THE SAME, AND METHOD FOR PRODUCING INFECTIOUS HEPATITIS C VIRUS PARTICLES
    Publication number: 20140302082
    Abstract: A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided.
    Type: Application
    Filed: March 30, 2012
    Publication date: October 9, 2014
    Applicants: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASE, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, TORAY INDUSTRIES, INC.
    Inventors: Takaji Wakita, Tomoko Date, Yasuhito Tanaka, Masashi Mizokami
  • MUTANT REPLICON DERIVED FROM GENOME OF HEPATITIS C VIRUS J6CF STRAIN
    Publication number: 20140302092
    Abstract: A nucleic acid includes the 5? untranslated region, a virus protein-coding region including the NS3 protein coding sequence, the NS4A protein coding sequence, the NS4B protein coding sequence, the NS5A protein coding sequence, and the NS5B protein coding sequence, and the 3? untranslated region of the HCV J6CF genome in that order from the 5? to 3? direction. The NS4A protein coding sequence has a mutation for substituting alanine at position 1680 with glutamic acid, as determined on the basis of the amino acid sequence of the precursor protein of the J6CF strain.
    Type: Application
    Filed: May 31, 2012
    Publication date: October 9, 2014
    Applicants: Toray Industries, Inc., Japan as Represented by Director-General of National Institute of Infectious Diseases
    Inventors: Takaji Wakita, Asako Murayama, Takanobu Kato
  • Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
    Patent number: 8852607
    Abstract: Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: October 7, 2014
    Assignee: Genzyme Corporation
    Inventors: Hema S. Sista, Yero J. Espinoza
  • Flavivirus vaccines
    Patent number: 8852914
    Abstract: The invention provides flavivirus vaccines and methods of making and using these vaccines.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: October 7, 2014
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Thomas P. Monath, Farshad Guirakhoo, Juan Arroyo, Konstantin V. Pugachev
  • Immunological herpes simplex virus antigens and methods for use thereof
    Patent number: 8852602
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: October 7, 2014
    Inventors: David M. Koelle, Lawrence Corey
  • Method of retrovirus storage
    Patent number: 8852915
    Abstract: A method of retrovirus storage, characterized in that a retrovirus is sustained in the presence of a substance with retrovirus binding activity immobilized on a solid phase. Further, there is provided a retrovirus composition characterized in that a retrovirus in the form of binding to a substance with retrovirus binding activity is sealed in a container holding a solid phase having the substance with retrovirus binding activity immobilized thereon.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: October 7, 2014
    Assignee: Takara Bio Inc.
    Inventors: Hideto Chono, Yasushi Katayama, Hiromi Okuyama, Junichi Mineno, Kiyozo Asada, Ikunoshin Kato
  • CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS
    Publication number: 20140294892
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Cyanine compounds and their application as quenching compounds
    Publication number: 20140295437
    Abstract: The present invention provides methods and non-fluorescent carbocyanine quencher compounds having the general formula: Wherein the A moiety is a substituted pyridinium, unsubstituted pyridinium, substituted quinolinium, unsubstituted quinolinium, substituted benzazolium, unsubstituted benzazolium, substituted indolinium, or substituted indolinium. The invention further provides luminescent donor molecule-quencher pairs and luminescent donor molecule-quencher-luminescent acceptor molecule conjugates wherein the quencher is a cyanine compound of the present invention. The energy transfer pairs are used to detect an analyte of interest in a sample.
    Type: Application
    Filed: December 17, 2013
    Publication date: October 2, 2014
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Rosaria HAUGLAND, Ching-Ying CHEUNG, Stephen YUE
  • INHIBITORS OF INFLUENZA VIRUSES REPLICATION
    Publication number: 20140296201
    Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Paul S. Charifson, Michael P. Clark, Upul K. Bandarage, Randy S. Bethiel, John J. Court, Hongbo Deng, Ioana Davies, John P. Duffy, Luc J. Farmer, Huai Gao, Wenxin Gu, Dylan H. Jacobs, Joseph M. Kennedy, Mark W. Ledeboer, Brian Ledford, Francois Maltais, Emanuele Perola, Tiansheng Wang, M. Woods Wannamaker, Randal Byrn, Yi Zhou, Chao Lin, Min Jiang, Steven Jones, Ursula A. Germann, Francesco G. Salituro, Ann Dak-Yee Kwong
  • RECOMBINANT NONPATHOGENIC MDV VECTOR PROVIDING MULTIVALENT IMMUNITY
    Publication number: 20140294893
    Abstract: The present invention relates to the field of veterinary vaccines, in particular to that of vector vaccines for poultry based on recombinant nonpathogenic Marek's disease virus (npMDV). The recombinant npMDV of the invention expresses stably and effectively two heterologous genes each originating from a different micro-organism: the fusion protein gene from Newcastle disease virus, and the viral protein 2 gene from infectious bursal disease virus. A vaccine based on this recombinant npMDV can be used to induce in poultry a protective immune response not only against Marek's disease, but also against Newcastle disease and Infectious bursal disease. The invention also relates to methods and uses involving the recombinant npMDV, expression cassette, infected host cells, and vaccines.
    Type: Application
    Filed: October 19, 2012
    Publication date: October 2, 2014
    Inventors: Paulus Jacobus Antonius Sondermeijer, Iwan Verstegen
  • NOVELPOLYPEPTIDES AND BACTERIOPHAGES SPECIFIC TO KLEBSIELLA PNEUMONIAE CAPSULAR TYPE STRAINS
    Publication number: 20140295528
    Abstract: The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 2, 2014
    Applicant: NATIONAL TAIWAN UNIVERSITY
    Inventors: Jin Town Wang, Tzu Lung Lin
  • Recombinant Adenovirus Vaccines
    Publication number: 20140294890
    Abstract: Recombinant adenovirus vaccines comprising recombinant adenoviruses whose hexon, fiber or protein IX capsid proteins are engineered to include exogenous peptide segments, e.g. vaccines for human papillomavirus (HPV) and malaria.
    Type: Application
    Filed: July 19, 2013
    Publication date: October 2, 2014
    Applicant: The Johns Hopkins University
    Inventors: Gary W. Ketner, Richard B.S. Roden, Fidel P. Zavala
  • RECOMBINANT BACULOVIRUS AND USE THEREOF
    Publication number: 20140295496
    Abstract: The present invention provides a recombinant baculovirus. The baculovirus has a genome into which a gene encoding ?-glutamyl carboxylase (GGCX) and a gene encoding DT-diaphorase (NQO1) are incorporated. The present invention further provides a method for producing a recombinant vitamin K-dependent protein by using the recombinant baculovirus.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Applicant: SYSMEX CORPORATION
    Inventors: Takahiko BANDO, Mutsumi SUGAI
  • MICROORGANISMS FOR THERAPY
    Publication number: 20140294891
    Abstract: Therapeutic methods and vaccinia virus therefor are provided. The viruses are designed so that they accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms.
    Type: Application
    Filed: June 11, 2014
    Publication date: October 2, 2014
    Inventors: Aladar A. Szalay, Tatyana Timiryasova, Yong A. Yu, Qian Zhang
  • Infectious genotype 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a hepatitis C virus lacking the hypervariable region 1 (HVR1)
    Patent number: 8846891
    Abstract: The present inventors used the previously developed H77/JFH 1T27OOC,A4O8OT (1a/2a), J4/JFH 1T2996C,A4827T,?HVRI (1b/2a), J6/JFH 1?HVRI (2a/2a), J8/JFH 1?HVRI (2b/2a), S52/JFH 1T27i8G,?7i6oc (3a/2a), SA13/JFH 1C34O5G,A3696G (5a/2a) and HK6a/JFH 1T1389c,A1590G (6a/2a) constructs for the deletion of Hypervariable Region 1 (HVR1) to construct viable, JFH 1 (genotype 2a) based, genomes. The present inventors serially passaged the viruses in cell culture obtaining relatively high HCV RNA titers and infectivity titers. Sequence analysis of the viruses identified mutations adapting H77/JFH 1T27OOC,A4O8OT,?HVR1 (1a/2a), J8/JFH 1?HVR1 (2b/2a), S52/JFH 1T2718G,T716OC,?HVR1 (3a/2a) and J4/JFH 1T2996C,A4827T,?HVR1 (1b/2a) to the HVR1 deletion.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: September 30, 2014
    Assignees: Hvidovre Hospital, Kobenhavns Universitet
    Inventors: Jannick Prento, Judith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
  • Bacteriophage and antibacterial composition comprising the same
    Patent number: 8846368
    Abstract: Disclosed herein is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella enteritidis, Salmonella typhimurium, Salmonella gallinarum, and Salmonella pullorum without affecting beneficial bacteria, in addition to showing excellent tolerance to acid, heat and desiccation. The novel bacteriophage of the present invention can be widely used as an active ingredient for therapeutic agents, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella enteritidis, Salmonella typhimurium, Salmonella gallinarum or Salmonella pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the Salmonella bacteria.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: September 30, 2014
    Assignee: CJ Cheiljedang Corporation
    Inventors: Soo An Shin, Min Tae Park, Hyang Choi, Young Wook Cho, In Hye Kang, Su Jin Choi
  • NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 3a
    Publication number: 20140286995
    Abstract: A nucleic acid includes, in the following order, a 5? untranslated region comprising a particular nucleotide sequence of the genome of hepatitis C virus genotype 3a; a nucleotide sequence encoding a particular amino acid sequence of an NS3 protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4B protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5B protein of the hepatitis C virus genotype 3a; and a 3? untranslated region comprising a particular nucleotide sequence of a genome of hepatitis C virus genotype 3a.
    Type: Application
    Filed: August 31, 2012
    Publication date: September 25, 2014
    Applicants: Japan as Represented by Director-General of National Institute of Infectious Diseases, Toray Industries, Inc., INSERM Institutut National de la Sante et de la Recherche Medicale
    Inventors: Takaji Wakita, Mohsan Saeed, Patrick Maurel, Claire Gondeau, Hiroshi Yokokawa
  • HEAT-RESISTANT NEWCASTLE DISEASE VIRUS LIVE VACCINE VECTOR SYSTEM AND USE THEREOF
    Publication number: 20140287496
    Abstract: A heat-resistant NDV live vaccine vector system includes a transcription plasmid, three helper plasmids, and host cells. The transcription plasmid is constructed by through cloning complete genomic cDNA of a heat-resistant NDV vaccine strain to a pBR322 vector. The three helper plasmids are constructed by cloning sequences coding nucleoprotein (NP), phosphoprotein, large polymerase protein of a heat-resistant NDV vaccine strain respectively to pcDNA3.1 vectors. A recombinant NDV artificially obtained by cotransfacting host cells with the transcription plasmid and the three helper plasmids shows heat-resistance.
    Type: Application
    Filed: June 24, 2013
    Publication date: September 25, 2014
    Inventors: Guoyuan Wen, Huabin Shao, Jun Yang, Honglin Wang, Qingping Luo, Rongrong Zhang, Diyun Ai, Ling Luo, Yu Shang, Jing Guo, Chen Chen
  • RECOMBINANT ADENOVIRUS COMPRISING TRANS-SPLICING RIBOZYME AND CANCER-TREATING GENE, AND USE THEREOF
    Publication number: 20140286905
    Abstract: The present invention relates to: a recombinant adenovirus comprising a polynucleotide, which encodes a trans-splicing ribozyme-HSVtk composite relating to a cancer-specific gene, and a cancer-treating gene; a pharmaceutical composition for preventing or treating cancer, containing the recombinant adenovirus as an active ingredient; and a method for treating cancer, comprising the step of administering the recombinant adenovirus or the pharmaceutical composition to an individual requiring treatment. The recombinant adenovirus of the present invention shows selectivity for a cancer cell by a trans-splicing ribozyme relating to a cancer-specific gene and an increased anticancer activity by a cancer-treating gene, and thus can be widely used for the effective prevention and treatment of cancer.
    Type: Application
    Filed: August 20, 2012
    Publication date: September 25, 2014
    Applicant: NATIONAL CANCER CENTER
    Inventor: Sang Jin Lee
  • CANINE INFLUENZA RECOMBINANT VIRUS, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
    Publication number: 20140286979
    Abstract: A canine influenza recombinant virus includes HA and NA genes of ZJCIV canine influenza virus as well as six internal genes PA, PB1, PB2, M, NP and NS of a PR8 virus. The nucleotide sequence of the HA gene is selected from the group consisting of: (1) a nucleotide sequence encoding an amino acid sequence of SEQ ID NO.1; (2) a nucleotide sequence encoding an amino acid sequence which has at least 98% sequence identity to the amino acid sequence of SEQ ID NO.1. The nucleotide sequence of the NA gene is selected from the group consisting of: (1) a nucleotide sequence encoding an amino acid sequence of SEQ ID NO.2; (2) a nucleotide sequence encoding an amino acid sequence which has at least 98% sequence identity to the amino acid sequence of SEQ ID NO.2.
    Type: Application
    Filed: April 26, 2012
    Publication date: September 25, 2014
    Applicant: SHANGHAI VETERINARY RESEARCH INSTITUTE, CAAS
    Inventors: Zejun Li, Qiaoyang Teng
  • DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES
    Publication number: 20140286983
    Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.
    Type: Application
    Filed: October 18, 2012
    Publication date: September 25, 2014
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
  • INFECTIOUS CLONES OF TORQUE TENO VIRUS
    Publication number: 20140286980
    Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length TTV genomes that can replicate efficiently in host animals and tissue culture.
    Type: Application
    Filed: May 24, 2012
    Publication date: September 25, 2014
    Applicant: ZOETIS LLC
    Inventor: Jacqueline Gayle Marx
  • BACTERIOPHAGE AND METHODS OF MAKING AND USING
    Publication number: 20140261478
    Abstract: Bacteriophage are provided, and methods of making and using the bacteriophage also are provided.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: Dongmei Xu, Elisabeth Miller, James Arthur Strickland, Ujwala Warek
  • VESICULAR STOMATITIS VIRUSES CONTAINING A MARABA VIRUS GLYCOPROTEIN POLYPEPTIDE
    Publication number: 20140271564
    Abstract: This document provides methods and materials related to vesicular stomatitis viruses containing a G polypeptide of a maraba virus. For example, vesicular stomatitis viruses containing a G polypeptide of a maraba virus (e.g., pseudotyped viruses), nucleic acid molecules encoding vesicular stomatitis viruses containing a G polypeptide of a maraba virus, methods for making vesicular stomatitis viruses containing a G polypeptide of a maraba virus, and methods for using vesicular stomatitis viruses containing a G polypeptide of a maraba virus to treat cancer or infectious diseases are provided.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Inventors: Stephen James Russell, Mulu Tesfay
  • COMPOSITIONS, ORGANISMS, SYSTEMS, AND METHODS FOR ALTERING COLD, DROUGHT, AND SALT TOLERANCE IN PLANTS
    Publication number: 20140283202
    Abstract: The present disclosure relates, in some embodiments, to materials, systems, organisms, and methods for enhancing abiotic stress tolerance (e.g., cold, salinity, drought, heat, wind) and/or enhancing biomass in plants. For example, enhancing abiotic stress tolerance may be achieved in plants having Arabidopsis thaliana BCL-2-associated athanogene 4 (AtBAG4) nucleic acids and/or polypeptides, Caenorhabditis elegans Ced-9 nucleic acids and/or polypeptides, and/or human Bcl-2-161 nucleic acids and/or polypeptides.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Martin B. Dickman, T. Erik Mirkov, Getu Beyene, Mayra Faion-Molina, Marco David Molina Risco
  • INFLUENZA VIRUS REASSORTMENT
    Publication number: 20140274806
    Abstract: Improved methods for the production of reassortant influenza viruses are provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicants: SYNTHETIC GENOMICS VACCINES, NOVARTIS AG
    Inventors: Derek O'Hagan, Peter Mason, Pirada Suphaphiphat, I, Daniel G. Gibson, David E. Wentworth, Timothy B. Stockwell, John I. Glass
  • DIGITAL TO BIOLOGICAL CONVERTER
    Publication number: 20140274808
    Abstract: The present invention provides a system for receiving biological sequence information and activating the synthesis of a biological entity. The system has a receiving unit for receiving a signal encoding biological sequence information transmitted from a transmitting unit. The transmitting unit can be present at a remote location from the receiving unit. The system also has an assembly unit connected to the receiving unit, and the assembly unit assembles the biological entity according to the biological sequence information. Thus, according to the present invention biological sequence information can be digitally transmitted to a remote location and the information converted into a biological entity, for example a protein useful as a vaccine, immediately upon being received by the receiving unit and without further human intervention after preparing the system for receipt of the information.
    Type: Application
    Filed: August 16, 2013
    Publication date: September 18, 2014
    Applicant: Synthetic Genomics, Inc.
    Inventors: J. Craig Venter, Daniel Gibson, John E. Gill
  • Therapeutic Cancer Vaccine Targeted to HAAH (Aspartyl-[Asparaginyl]-beta-Hydroxylase)
    Publication number: 20140271689
    Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: PANACEA PHARMACEUTICALS
    Inventors: Biswajit Biswas, Carl R. Merril, Hossein A. Ghanbari